Forge Biologics to Participate in Upcoming Investor Conferences and Presentations in March 2022 - Forge Biologics

Forge Biologics to Participate in Upcoming Investor Conferences and Presentations in March 2022


COLUMBUS, Ohio – March 7, 2022 Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that members of the Company’s leadership team will be participating at the following upcoming investor conferences in March:

Cowen 42nd Annual Virtual Health Care Conference
Dates: March 7-9, 2022
Format: 1×1 investor meetings

Oppenheimer Fireside Chat
Date: March 14, 2022
Time: 11:00 a.m. Eastern Time
Title: “AAV-based Gene Therapy: Navigating Regulatory and CMC Landscape”
Presenters: Timothy J. Miller, Ph.D., Chief Executive Officer of Forge Biologics
RA Session, II, Chief Executive Officer of Taysha Gene Therapies
Rachel Potter, Ph.D., Head of Gene Therapy Research at Sarepta Therapeutics
Moderators: Kevin DeGeeter, Senior Analyst, Biotechnology and Diagnostics
Hartaj Singh, Senior Analyst, Biotechnology

Oppenheimer 32nd Annual Virtual Healthcare Conference
Dates: March 15-17, 2022
Format: 1×1 investor meetings

Date: March 17, 2022
Time: 10:40 a.m. Eastern Time
Format: Company presentation
Presenter: Timothy J. Miller, Ph.D., CEO, President and Co-Founder of Forge Biologics

Dr. Miller’s Oppenheimer company presentation will be delivered via live webcast and may be accessed for 90 days by visiting Forge’s Events website at

About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 200,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.  To learn more, visit

Media Inquiries
Marina Corleto – Forge Biologics
Senior Manager, Marketing and Communications   

Business Development  
Magdalena Tyrpien – Forge Biologics
Senior Vice President, Head of Business Development   

Client Development
John Maslowski, M.S. – Forge Biologics
Chief Commercial Officer

Investor Relations  
Christina Perry – Forge Biologics
Senior Vice President, Finance and Investor Relations   


0/5 (0 Reviews)